INDV News & Events

Indivior Pharmaceuticals announced completion of its redomiciliation from the United Kingdom to the United States. As a result, Indivior Pharmaceuticals, a new Delaware corporation, has become the new parent company. Indivior PLC is renamed Indivior and has become a wholly-owned subsidiary of IPI. The common stock of Indivior Pharmaceuticals is listed on Nasdaq and will continue to trade under the symbol "INDV."

"2025 was a transition year for Indivior in which we established the Indivior Action Agenda and completed Phase I - Generate Momentum - by growing U.S. SUBLOCADE net revenue, simplifying the organization and transforming our operating model," said Joe Ciaffoni, Chief Executive Officer. "We enter 2026 well positioned to execute on Phase II - Accelerate - which includes accelerating U.S. SUBLOCADE dispense unit growth and SUBLOCADE net revenue throughout 2026 and immediately accelerating adjusted EBITDA and cash flow at a faster rate."